JP2024527401A - 神経学的疾患を処置する方法 - Google Patents

神経学的疾患を処置する方法 Download PDF

Info

Publication number
JP2024527401A
JP2024527401A JP2024501831A JP2024501831A JP2024527401A JP 2024527401 A JP2024527401 A JP 2024527401A JP 2024501831 A JP2024501831 A JP 2024501831A JP 2024501831 A JP2024501831 A JP 2024501831A JP 2024527401 A JP2024527401 A JP 2024527401A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
antibodies
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527401A5 (https=
Inventor
シュイ－オン レオン，
チホ チョン，
チンイー チュアン，
Original Assignee
サイノマブ バイオサイエンス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイノマブ バイオサイエンス リミテッド filed Critical サイノマブ バイオサイエンス リミテッド
Publication of JP2024527401A publication Critical patent/JP2024527401A/ja
Publication of JP2024527401A5 publication Critical patent/JP2024527401A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2024501831A 2021-07-13 2022-07-12 神経学的疾患を処置する方法 Pending JP2024527401A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221261P 2021-07-13 2021-07-13
US63/221,261 2021-07-13
PCT/CN2022/105077 WO2023284710A1 (en) 2021-07-13 2022-07-12 Methods of treating neurological diseases

Publications (2)

Publication Number Publication Date
JP2024527401A true JP2024527401A (ja) 2024-07-24
JP2024527401A5 JP2024527401A5 (https=) 2025-07-22

Family

ID=84919904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501831A Pending JP2024527401A (ja) 2021-07-13 2022-07-12 神経学的疾患を処置する方法

Country Status (10)

Country Link
US (1) US20240309089A1 (https=)
EP (1) EP4370153A4 (https=)
JP (1) JP2024527401A (https=)
KR (1) KR20240042443A (https=)
CN (1) CN117999096A (https=)
AU (1) AU2022310081A1 (https=)
CA (1) CA3225077A1 (https=)
MX (1) MX2024000591A (https=)
WO (1) WO2023284710A1 (https=)
ZA (1) ZA202400405B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3710471A1 (en) * 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
WO2024197258A1 (en) * 2023-03-23 2024-09-26 Klaritos, Inc Methods of treating alzheimer's disease
WO2025190311A1 (en) * 2024-03-12 2025-09-18 Sinomab Bioscience Limited Method of identifying anti-siglec antibodies possessing cis-trans converter properties, anti-siglec antibodies and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9066928B1 (en) * 2012-12-04 2015-06-30 University Of Kentucky Research Foundation Method, composition, and kit useful for treatment of alzheimer's disease
AU2014305658A1 (en) * 2013-08-05 2016-02-11 St. Vincent's Institute Of Medical Research An antibody therapy for amyloid beta disease
WO2017196432A1 (en) * 2016-05-12 2017-11-16 La Jolla Institute For Allergy And Immunology Compositions and methods for diagnosing and treating neurodegenerative disease
EP3867280A4 (en) * 2018-10-18 2022-11-09 Sinomab Bioscience Limited METHODS OF TREATMENT OF RHEUMATOID ARTHRITIS
ES2821599A1 (es) * 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer

Also Published As

Publication number Publication date
KR20240042443A (ko) 2024-04-02
WO2023284710A1 (en) 2023-01-19
EP4370153A1 (en) 2024-05-22
ZA202400405B (en) 2025-03-26
EP4370153A4 (en) 2025-05-07
MX2024000591A (es) 2024-03-19
CA3225077A1 (en) 2023-01-19
CN117999096A (zh) 2024-05-07
AU2022310081A1 (en) 2024-02-01
US20240309089A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
AU2022252753B2 (en) ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF
AU2022203601A1 (en) Therapeutic antibodies and their uses
CN101820911B (zh) β淀粉样蛋白的人源化抗体
CN107531786B (zh) 抗axl拮抗抗体
TWI449535B (zh) 針對類澱粉- β肽之抗體於治療年齡相關黃班退化之用途
JP2021061854A (ja) ＦｃＲｎ抗体およびその使用方法
JP2021527110A (ja) ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用
JP2022002545A (ja) 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途
WO2023284710A1 (en) Methods of treating neurological diseases
KR20130136968A (ko) 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
AU2009322587B2 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
WO2023202553A1 (en) Methods of treating neurological diseases
HK40109637A (zh) 治疗神经学疾病的方法
HK40121519A (zh) 治疗神经系统疾病的方法
HK40096197A (zh) 抗axl拮抗抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250711